FDA Approves New Treatment for ALK+ NSCLC Patients

2018-11-05T14:35:44+00:00November 2nd, 2018|Hot Topics, News|

Friday, November 2, 2018 – Today the Food and Drug Administration (FDA) granted accelerated approval to lorlatinib (LORBRENA) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.Click here to learn more. 

Highlights from World Conference on Lung Cancer

2018-10-01T13:48:43+00:00September 27th, 2018|Events, Hot Topics, News|

This week, the LCA team attended the 19th Annual World Conference on Lung Cancer (September 23-26, 2018) in Toronto, Canada. Jennifer C. King, PhD, Director of Science and Research, gives us the scoop on some of the research and treatment breakthroughs, and how they impact you! https://youtu.be/Q2S7akrHUVQ SCREENING REDUCES MORTALITY! Results from the Dutch-Belgium Lung Cancer Screening trial (NELSON) showed that lung cancer screening significantly reduces lung cancer mortality. In this trial, which was more favorable than the National Lung [...]

FDA Approves First-Line Treatment for NSCLC with ALK Biomarker

2018-03-23T14:58:25+00:00November 7th, 2017|Hot Topics, News|

Monday, November 6, 2017 - The United States Food and Drug Administration (FDA) approved Alecensa (alectinib) as a first treatment for advanced non-small cell lung cancer that is positive for a biomarker called ALK.  Alecensa was already approved for ALK+ lung cancer that was resistant to other ALK-targeted therapies. Now, a large randomized clinical trial showed that Alecensa was more effective than previous first-line treatment.  Patients had an average of 25.7 months without their cancer progressing (getting worse) when taking [...]

No announcement available or all announcement expired.